| KuDOS Pharmaceuticals holds a leading position
in the discovery and development of drugs based upon the science of
DNA damage sensing, signalling and repair to address unmet
medical needs in cancer treatment.
We use rational drug discovery techniques to create potent and
selective small molecule inhibitors with specific activity against
individual DNA repair pathways. KuDOS research indicates that inhibition
of selected pathways can significantly enhance the clinical effectiveness
of radiotherapy and various chemotherapeutics.
KuDOS has built closely knit research and development teams
that can expedite candidate compounds through to the clinic.
We are committed to improving therapy for cancer patients by
building strong international collaborations to fully realize the
potential of our products.
On 31st Jan 2006, KuDOS was aquired and is now a wholly owned subsidiary of AstraZeneca. |
